BioAtla Statistics
Total Valuation
BioAtla has a market cap or net worth of $2.89 million. The enterprise value is $7.21 million.
| Market Cap | 2.89M |
| Enterprise Value | 7.21M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAtla has 1.67 million shares outstanding. The number of shares has increased by 28.86% in one year.
| Current Share Class | 1.67M |
| Shares Outstanding | 1.67M |
| Shares Change (YoY) | +28.86% |
| Shares Change (QoQ) | +10.66% |
| Owned by Insiders (%) | 7.48% |
| Owned by Institutions (%) | 12.17% |
| Float | 1.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.20
| Current Ratio | 0.20 |
| Quick Ratio | 0.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -105.86% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 269.43% |
| Weighted Average Cost of Capital (WACC) | 2.78% |
| Revenue Per Employee | $207,317 |
| Profits Per Employee | -$767,171 |
| Employee Count | 41 |
| Asset Turnover | 0.46 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.23% in the last 52 weeks. The beta is 0.76, so BioAtla's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -92.23% |
| 50-Day Moving Average | 3.53 |
| 200-Day Moving Average | 12.79 |
| Relative Strength Index (RSI) | 20.14 |
| Average Volume (20 Days) | 125,763 |
Short Selling Information
The latest short interest is 138,890, so 8.34% of the outstanding shares have been sold short.
| Short Interest | 138,890 |
| Short Previous Month | 105,433 |
| Short % of Shares Out | 8.34% |
| Short % of Float | 10.09% |
| Short Ratio (days to cover) | 2.98 |
Income Statement
In the last 12 months, BioAtla had revenue of $8.50 million and -$31.45 million in losses. Loss per share was -$22.74.
| Revenue | 8.50M |
| Gross Profit | -16.06M |
| Operating Income | -31.03M |
| Pretax Income | -31.45M |
| Net Income | -31.45M |
| EBITDA | -30.83M |
| EBIT | -31.03M |
| Loss Per Share | -$22.74 |
Balance Sheet
The company has $1.54 million in cash and $5.86 million in debt, with a net cash position of -$4.32 million or -$2.59 per share.
| Cash & Cash Equivalents | 1.54M |
| Total Debt | 5.86M |
| Net Cash | -4.32M |
| Net Cash Per Share | -$2.59 |
| Equity (Book Value) | -36.24M |
| Book Value Per Share | -21.79 |
| Working Capital | -16.76M |
Cash Flow
| Operating Cash Flow | -23.48M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 195,000 |
| Net Borrowing | 7.13M |
| Free Cash Flow | -23.48M |
| FCF Per Share | -$14.09 |
Margins
| Gross Margin | -188.92% |
| Operating Margin | -365.00% |
| Pretax Margin | -370.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAtla does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.86% |
| Shareholder Yield | -28.86% |
| Earnings Yield | -1,088.12% |
| FCF Yield | -812.33% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 6, 2026. It was a reverse split with a ratio of 1:50.
| Last Split Date | Apr 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
BioAtla has an Altman Z-Score of -92.9 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -92.9 |
| Piotroski F-Score | 3 |